![](/img/cover-not-exists.png)
First-Line Pembrolizumab in PD-L1 Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis from A UK Healthcare Perspective
Hu, X, Goldman, DPVolume:
20
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2017.08.006
Date:
October, 2017
File:
PDF, 226 KB
english, 2017